<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed data on 612 patients who had undergone high-dose chemoradiotherapy (HDT) with autologous stem cell rescue for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) at the City of Hope National Medical Center, to evaluate the incidence of therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and associated risk factors </plain></SENT>
<SENT sid="1" pm="."><plain>A retrospective cohort and a nested case-control study design were used to evaluate the role of pretransplant therapeutic exposures and transplant conditioning regimens </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-two patients developed morphologic evidence of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The estimated cumulative probability of developing morphologic t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 8.6% +/- 2.1% at 6 years </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate analysis of the entire cohort revealed stem cell priming with <z:chebi fb="0" ids="4911">VP-16</z:chebi> (RR = 7.7, P = 0.002) to be independently associated with an increased risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The influence of pretransplant therapy on subsequent t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> risk was determined by a case-control study </plain></SENT>
<SENT sid="6" pm="."><plain>Multivariate analysis revealed an association between pretransplant radiation and the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but failed to reveal any association with pretransplant chemotherapy or conditioning regimens </plain></SENT>
<SENT sid="7" pm="."><plain>However, patients who had been primed with <z:chebi fb="0" ids="4911">VP-16</z:chebi> for stem cell mobilization were at a 12 </plain></SENT>
<SENT sid="8" pm="."><plain>3-fold increased risk of developing t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with 11q23/21q22 abnormalities (P = 0.006) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients undergoing HDT with stem cell rescue are at an increased risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, especially those receiving priming with <z:chebi fb="0" ids="4911">VP-16</z:chebi> for peripheral stem cell collection </plain></SENT>
<SENT sid="10" pm="."><plain>(Blood </plain></SENT>
<SENT sid="11" pm="."><plain>2000;95:1588-1593) </plain></SENT>
</text></document>